Associated tags: Hospital, Pharmacy, Health, Research, Patient, Cancer, Conference, Future, Pharmaceutical industry, National Cancer Institute, DSM-IV codes, Policy, Foreign Policy, Bristol Myers Squibb, Child, Face, Assistant, World Bank Group, Nutrition, Dana–Farber Cancer Institute, Alternative, World Bank, Chairperson
Locations: UAE
Retrieved on:
Tuesday, December 19, 2023
Conference,
National Cancer Institute,
Alternative,
Partnership,
World Bank,
Research,
Chairperson,
Dana–Farber Cancer Institute,
White,
Cancer Moonshot,
Brigham and Women's Hospital,
Congress,
Society,
Cancer,
Health equity,
AI,
Nutrition,
Future,
Assistant,
Face,
Child,
Patient,
Bristol Myers Squibb,
Foreign Policy,
Policy,
World Bank Group WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
Key Points:
- With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
- Hannah Adams, a pediatric cancer survivor, reminded the audience that "the most effective advocates put a face and a name to the child of cancer."
- The Future of Cancer Care panel delved into the potential of AI, equity considerations, and global access.
- The Burjeel Holdings Oncology Conference served as a powerful call to action, urging individuals to support research, advocate for patient-centered policies, and raise awareness.
Retrieved on:
Tuesday, December 19, 2023
Conference,
National Cancer Institute,
Alternative,
Partnership,
World Bank,
Research,
Chairperson,
Dana–Farber Cancer Institute,
White,
Cancer Moonshot,
Brigham and Women's Hospital,
Congress,
Society,
Cancer,
Health equity,
AI,
Nutrition,
Future,
Assistant,
Face,
Child,
Patient,
Bristol Myers Squibb,
Foreign Policy,
Policy,
World Bank Group WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
Key Points:
- With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
- Hannah Adams, a pediatric cancer survivor, reminded the audience that "the most effective advocates put a face and a name to the child of cancer."
- The Future of Cancer Care panel delved into the potential of AI, equity considerations, and global access.
- The Burjeel Holdings Oncology Conference served as a powerful call to action, urging individuals to support research, advocate for patient-centered policies, and raise awareness.
FGFR,
Canavan disease,
Partnership,
PALO,
Pantothenate kinase-associated neurodegeneration,
Clinical trial,
Needs assessment,
ABU,
Congenital adrenal hyperplasia,
Achondroplasia,
Research,
DSM-IV codes,
Innovation Center station,
Craniosynostosis,
Methylmalonic acidemia,
Rare,
Hospital,
HIV disease progression rates,
New Jersey Department of Health,
Patient,
Risk,
Propionic acidemia,
Algorithm,
Cancer,
Genetic testing,
Diagnosis,
Emirate,
Health,
Therapy,
Doh,
Hypochondroplasia,
Pharmaceutical industry ABU DHABI, United Arab Emirates and PALO ALTO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Burjeel Holdings, one of the largest healthcare providers in the MENA region, and BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, have announced a new project to revolutionize the field of early diagnosis and treatment of rare diseases or disorders in the UAE and the region. The two entities signed a preliminary, non-binding Collaboration Agreement establishing a mutual intention to work together on project ‘NADER’ (Needs Assessment and Therapeutics Development for Rare Diseases – ‘nader’ meaning ‘rare’ in Arabic). Genetic in origin, these often life-threatening or chronically debilitating diseases affect a small percentage of the population and are present throughout the person's entire life, even if symptoms do not immediately appear. The partnership will launch operations in Abu Dhabi to conduct clinical trials and research, leveraging the Emirate’s advanced infrastructure for innovation and life science.
Key Points:
- The partnership will launch operations in Abu Dhabi to conduct clinical trials and research, leveraging the Emirate’s advanced infrastructure for innovation and life science.
- Project ‘NADER’ aims to revolutionize the field of early diagnosis and treatment in order to potentially improve patient outcomes.
- Dr. Khaled Musallam, Group Chief Research Officer of Burjeel Holdings and project lead said, “Many rare diseases are highly clustered in our region due to our unique genetic pool.
- As the collaboration unfolds, both Burjeel Holdings and BridgeBio anticipate significant progress in the field of rare diseases in the region.
Research,
Neurology,
Hospitals,
Clinical Trials,
Health Technology,
Health Insurance,
Health,
Pharmaceutical,
Science,
Epilepsy,
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,
BMC,
Donald,
Partnership,
Rockefeller Neuroscience Institute,
DSM-IV codes,
Multimedia,
Department of Neurology, Xuanwu hospital,
Multiple sclerosis,
Northwell Health,
Organization,
MD,
Patient,
Knowledge,
MENA,
SVP,
Nursing,
Management,
Pharmaceutical industry The collaboration between Burjeel Holdings and Northwell Health will enable the transfer of knowledge and expertise between the two organizations to deliver the best possible patient care.
Key Points:
- The collaboration between Burjeel Holdings and Northwell Health will enable the transfer of knowledge and expertise between the two organizations to deliver the best possible patient care.
- View the full release here: https://www.businesswire.com/news/home/20230609005314/en/
Northwell Health and Burjeel Holdings signed a Memorandum of Understanding to open the Dr. Najjar Neuroscience Institute in the UAE.
- From left are John Sunil, CEO of Burjeel Holdings; Souhel Najjar, MD, senior vice president and executive director of the neurology service line of Northwell Health; and Michael Dowling, president and CEO of Northwell Health.
- The ceremony was attended by Dr. Shamsheer Vayalil, founder and chairman of Burjeel Holdings; Mr. John Sunil, CEO, Burjeel Holdings; Dr. Mohan Chellappa, non-executive director, Burjeel Holdings; Michael Dowling, president and CEO, Northwell Health; Dr. Souhel Najjar, SVP and executive director of the Neurology Service Line, Northwell Health; Dinelia Ortiz, vice president, Neurology Service Line, Northwell Health; Serena Najjar, senior project manager, Neurology Global Patient Services, Northwell Health; Kevin Beiner, SVP and regional executive director western region, Northwell Health.
